Chapter 35
Pneumonia Virus of Mice (PVM): Exploring Novel Therapeutic Options In a Severe Respiratory Disease Model

Helene F. Rosenberg and Joseph B. Domachowske

35.1 Introduction

Respiratory syncytial virus (RSV) is the most important respiratory pathogen among infants and toddlers, with infections prevalent and nearly universal in this age group. Severe infections are more common among premature infants, those with cardiac and pulmonary anomalies, and the immunosuppressed. Effective prophylactic monoclonal antibody treatment is available for high-risk infants, but there is no effective vaccine. Mouse challenge models have been used for the study of the human RSV pathogen, but the most severe forms of RSV disease are not replicated by this approach. Pneumonia virus of mice (PVM; family Paramyxoviridae, genus Pneumovirus) is a mouse pathogen of the same family as human respiratory syncytial virus. PVM replicates efficiently in mouse-lung epithelial cells in vivo in response to a minimal virus inoculum, and replication is accompanied by local production of proinflammatory cytokines (MIP-1α, MIP-2, MCP-1, and IFN-γ) and granulocyte recruitment to the lung. PVM infection and the ensuing inflammatory response can lead to pulmonary edema and respiratory compromise. Our laboratories have pioneered the use of the PVM model for the study of human clinical disease, which has provided important insights into the role of the inflammatory response in the pathogenesis of severe respiratory virus infection. As part of this work, we have presented several immunomodulatory strategies that clearly reduce morbidity and mortality when administered to PVM infected, symptomatic mice, and thus hold promise as realistic therapeutic strategies for severe RSV infection in human subjects.

35.2 Human RSV Disease

Respiratory syncytial virus (RSV) infection is a near universal affliction of infancy and childhood, accounting for approximately 50% of all pneumonia and up to 90% of the reported cases of bronchiolitis in infancy. Of those infected during the first year of life, one-third develops lower respiratory tract disease, and 2.5% are hospitalized (more than 90,000 children in the United States every year). In many previously healthy infants, RSV disease is a mild and self-limited infection involving the upper and lower respiratory tract, with varying degrees of peribronchial and interstitial inflammation. In others, the disease progresses to severe bronchiolitis and pneumonia, including submucosal edema and bronchiolar obstruction requiring oxygen, and in the worst cases, mechanical ventilation. Infants at particularly high risk for severe disease include those born prematurely, infants and children with cardiac or pulmonary anomalies, and the immunocompromised. Prophylactic monoclonal antibody therapy is available for high-risk infants, but no vaccine is yet approved for use. RSV has also recently been recognized as an important pathogen in the institutionalized elderly. The clinical features and pathology of RSV disease have been reviewed extensively, and the reader is referred to these excellent sources of additional information [1–4].

35.3 Identifying an Appropriate Animal Model

There is no one animal model that can replicate all features of a human disease. This is particularly true when considering infectious pathogens, many of which have particular tropisms or specificities for a limited range of hosts, and in some cases present with completely different clinical illnesses in different species. While it would perhaps be ideal to study all human pathogens in natural, relevant human or higher primate hosts, this approach is of course completely limited and impractical. Despite clear and recognized differences between human and rodent immune and inflammatory responses, various factors (availability of characterized strains, ease of handling and breeding, availability of sophisticated experimental tools). together have provided a focus on inbred strains of mice as a centerpiece for human disease research. As such, it is critical that one understands what the unique features of each infectious disease model are and that
the specific advantages and the individual limitations in each situation are clearly understood.

With these factors in mind, around 1997, we began our collaborative exploration of the pneumonia virus of mice (PVM) pathogen for the study of respiratory virus replication and the ensuing inflammatory response within a natural, evolutionarily relevant host-pathogen relationship. Further and more detailed consideration of our studies and those from other laboratories can be found in several of our recent reviews [5–8]; this article is largely excerpted from ref. 8.

### 35.4 The Pneumonia Virus of Mice Pathogen

PVM was originally discovered in 1939 by Frank Horsfall and Richard Hahn at the Rockefeller University as part of an attempt to identify pathogens from human clinical samples that would replicate in lung tissues of inbred mice [9]. Interestingly, PVM was isolated from lung tissue from the control (thought to be uninfected) mice, which yielded an infectious isolate after undergoing serial mouse-to-mouse passage. Choppin and colleagues [10] presented the first electron micrographs of these newly discovered virions (Fig. 35.1), which they described as defining a new, third subgroup of myxoviruses. The polymorphic virions formed spheres of 80–120 millimicrons in diameter to filaments up to three microns in length, and replicated over a period of 24–30 hours in mouse lung tissue in vivo, with virus amplification proceeding at ~16-fold per cycle. Perhaps most interestingly, Ginsberg and Horsfall [11] recognized the potential of PVM for the exploration of acute respiratory virus infection in an evolutionarily relevant host. Among several studies, these authors were the first to relate the development of lung lesions to ongoing virus replication and to evaluate altered morbidity and mortality in response to rudimentary immunomodulatory therapy, specifically in response to administration of bacterial capsular polysaccharide [11–13].

PVM has since been classified as a pneumovirus (Family Paramyxoviridae, genus Pneumovirus), together with the human and bovine respiratory syncytial virus pathogens. Viruses of this family are enveloped, and have non-segmented, negative-sense RNA genomes [14]. The molecular organization of the PVM genome has been elucidated primarily by Easton and colleagues [15–18], and has been the subject of several recent reviews [5,6]. The genomic organizations of PVM and RSV are shown in Fig. 35.2, which highlights the similarities in gene structure and gene order.

There are two major characterized strains of PVM in general use, although there is not complete clarity on all details related to their origin and maintenance. The original studies by Horsfall and colleagues [9,11–13] were performed on an isolate known as strain 15, which was at that time highly pathogenic in mice. Since that time, PVM strain 15 has reportedly undergone tissue-culture passage and lost some of its pathogenicity in vivo, although the extent to which this is so, and in which specific isolates, remains uncertain. A second strain, PVM strain J3666, also developed at the Rockefeller University, has been reportedly maintained in mice with minimal tissue-culture passage, and has recently been shown to be highly pathogenic in nearly all inbred strains of mice [19]. In our hands, PVM strain 15 from Dr. Andrew Easton's laboratory (PVM strain 15 Warwick) is highly attenuated and elicits

![Fig. 35.1](image-url)  
Electron microscopic image of nascent PVM virions. Virions as shown budding (at arrow) from BHK-21 cells in culture. Reprinted with permission from Compans, R. W., et al. [10]

![Fig. 35.2](image-url)  
Genomic organization of RSV and PVM. Shown are the 3' to 5' linear order of PVM and RSV protein encoding genes, including non-structural proteins (NS1 and NS2), nucleoprotein (N), phosphoprotein (P), matrix protein (M), surface hydrophobic protein (SH), attachment protein (G), fusion protein (F), the M2 genes, and polymerase protein (L). Reprinted with permission from Rosenberg, et al. [5]
a minimal inflammatory response in the highly susceptible BALB/c strain of mice [20]. In contrast, PVM strain 15 from the American Type Culture collection (PVM strain 15 ATCC) is pathogenic in BALB/c mice (unpublished findings), but results in little to no disease in the less susceptible C57BL/6 strain at similar inoculating doses (<100 pfu/mouse [21]). Krempl and colleagues [22] likewise found PVM strain 15 (ATCC) to be highly pathogenic in the BALB/c strain. Complete sequence data are available for both PVM strain J3666 and PVM strain 15 [23,24]. The most remarkable differences are in selected regions of the G (attachment protein) and throughout the sequence of the SH small hydrophobic glycoprotein.

### 35.5 RSV and PVM: Inflammatory Responses and Disease Severity

We became interested in PVM in order to pursue studies of inflammatory responses to respiratory virus infections in a natural, evolutionarily relevant host. We initially recapitulated the aforementioned findings of Horsfall and colleagues and reported robust virus replication in situ (to titers >10⁸ pfu/gm lung tissue), progressing to marked morbidity (hunching, fur ruffling), weight loss, and mortality, in our case in response to a minimal virus inoculum of the highly pathogenic strain PVM J3666 [25,26]. We have localized immunoreactive PVM to the bronchiolar epithelium [27], in a distribution similar to what has been observed for RSV in human post-mortem specimens [28] (Fig. 35.3). Microscopic examination of bronchoalveolar lavage fluid and lung tissue from morbid mice revealed profound inflammation, most notable for recruitment of granulocytes and for severe pulmonary edema consistent with the clinical findings characteristic of acute respiratory distress syndrome (ARDS; Fig. 35.4). Interestingly, severe inflammation, edema and recruitment of granulocytes have also been characterized in a recent series of RSV-diagnosed post-mortem samples evaluated by Welliver and colleagues [28]. PVM replication in situ results in local production of proinflammatory mediators, including MIP-1α, MIP-2, MCP-1 and IFN-γ [27]. A similar subset of proinflammatory mediators is produced in association with the more severe forms of RSV in human infants (reviewed in ref. 29).

Similar to findings from the mouse model of influenza virus [30] we found that the chemokine, MIP-1α (CCL3), is crucial for granulocyte recruitment in response to PVM infection [26]. Specifically, MIP-1α gene-deleted mice are readily infected with PVM, although 10⁵-fold fewer granulocytes are recruited to the lung tissue in response to the identical initial inoculum. Similar results were obtained upon infecting mice devoid of CCR1, the major receptor for MIP-1α on neutrophils and eosinophils. We have used this observation to design specific immunomodulatory strategies for the virus-induced inflammatory response and its associated pathology [31,32]

---

**Fig. 35.3** Detection of immunoreactive PVM and RSV in bronchiolar epithelial cells. (a) Immunoreactive PVM is detected in infected mouse lung tissue by probing with convalescent mouse sera, original magnification 20X. (b) as in (a), original magnification 40X. (c) Detection of immunoreactive RSV in post-mortem human lung tissue, original magnification 40X. PVM images reprinted with permission from Bonville, et al. [27]; RSV images reprinted with permission from Welliver, et al. [28]

**Fig. 35.4** Lung pathology. (a) Lung tissue from infected mice, with region of typical grey discoloration and multiple hemorrhagic foci; reprinted with permission from Ellis, et al. [21]; (b) Microscopic pathology, with evidence of profound cellular inflammatory response and developing pulmonary edema; original magnification, 20X, reprinted with permission from Garvey, et al. [36]; (c) Bronchoalveolar lavage fluid, with recruited neutrophils, original magnification, 63X
(discussed further below). Interestingly, although MIP-1α is clearly crucial for granulocyte recruitment in response to PVM infection, this chemokine, acting alone, even at high concentrations, does not induce ARDS, nor does it recruit granulocytes effectively in the absence of IFN-γ [33].

### 35.5.2 Inflammatory Responses In Aged Mice

As noted above, respiratory virus infection is also a growing problem in the aging population [34]. In a study performed using young adult (eight–12 weeks) through aged (up to 78 weeks), but otherwise immunologically naïve mice, we observed no change in the kinetics of PVM replication, but diminished local production of several proinflammatory mediators, including MIP-1α, MCP-1, and IFN-γ, along with diminished recruitment of granulocytes to the lung tissue [35]. The differences observed when comparing these results to those reported among elderly human subjects, who tend to have more severe, rather than less severe forms of RSV infection, may be related to virus re-exposure and its impact on the ensuing biochemical and cellular inflammatory responses. Interestingly, there is no published data on PVM replication and disease pathogenesis in neonatal mice, a critical target population given the prevalence of pneumovirus infection among human infants and toddlers.

### 35.5.3 Differential Responses In Type I IFN Receptor Gene-Deleted Mice

Pneumoviruses have unusual anti-interferon strategies, as they do not limit IFN production, nor do they interfere with receptor binding or signal transduction. Of particular recent interest are the ways in which IFNs and IFN-mediated signaling mechanisms interact with proinflammatory pathways and modulate the production of chemoattractant cytokines. As part of a larger exploration of the inflammatory responses to PVM, we examined the differential expression of cytokine genes in wild-type mice and mice devoid of the receptor for type I interferons (IFNαβR gene-deleted mice) [36]. As anticipated, PVM infection induces transcription of IFN antiviral response genes preferentially in lung tissue of wild-type over IFNαβR gene-deleted mice. However, we demonstrate that PVM infection also results in enhanced expression of eotaxin-2, TARC, and the proinflammatory RNase mouse eosinophil-associated RNase (mEar) 11, and we observe paradoxically prolonged survival among the IFNαβR gene-deleted mice.

### 35.6 Immunity to PVM Generated via Mucosal Inoculation

Using PVM strain 15 (ATCC), which, as noted above, is attenuated (replication-competent but does not induce a profound inflammatory response) in the C57BL/6 mouse strain, we explored the development of acquired immunity in response to a mucosal vaccination strategy. Neutralizing antibodies were detected at 14 days after inoculation in mice receiving live attenuated virus (but not heat-inactivated virus), which correlated with protection against subsequent challenge with the highly pathogenic strain J3666 [21]. Among the interesting questions, we are not certain of the duration of protective immunity. Interestingly, the responses of IFNγR gene-deleted mice were indistinguishable from the wild-type mice, indicating that any role for IFN-γ in generating acquired immunity in this setting is at least somewhat dispensable (Fig. 35.5). Among our other findings, PVM antigens, when prepared and administered in a manner analogous to the earlier hRSV lot 100 vaccine [37], will induce a Th2-mediated hypersensitivity response [38].

### 35.7 Therapeutic Strategies

Among the primary reasons to explore respiratory virus infection using the PVM model is to improve our understanding of the molecular basis of severe disease so as to design novel therapeutic strategies.
35.7.1 Antiviral Agents

The antiviral agent, ribavirin, is very effective at blocking replication of RSV in both tissue culture and in human subjects, yet the impact of ribavirin therapy alone on the course of actual clinical disease is insignificant [39]. The PVM model replicates this scenario, as ribavirin at concentrations of >10 µg/ml is effective at blocking virus replication in tissue culture, and at concentrations of 75 µg/kg/day, at blocking virus replication in mouse lung tissue in vivo. Yet, analogous to observations made in clinical studies, administration of effective doses of ribavirin alone to PVM-infected, symptomatic mice, has little impact on the ultimate outcome of disease, when measured in terms of morbidity and mortality [31,32]. In conjunction with this observation, we found that, although ribavirin was quite effective at blocking virus replication, it had no impact on the ongoing production of proinflammatory chemokines and associated recruitment of granulocytes to the lung tissue. Clearly, there is some disconnect between virus replication and the ensuing inflammatory response, in that inflammation is not necessarily controlled effectively at all given points in time by reducing or eliminating the primary stimulus.

35.7.2 Glucocorticoids

Glucocorticoids are in general use as broad-spectrum, anti-inflammatory agents, yet overall analysis suggests that they have only limited benefit for the treatment of severe hRSV-associated inflammation [40]. Although we have not evaluated specific combinations of ribavirin and glucocorticoids in PVM-infected mice, we have documented the effects of hydrocortisone alone on the inflammatory response. We have determined that hydrocortisone therapy has no effect on the production of MIP-1α or on the influx of neutrophils; PVM-infected mice responded to hydrocortisone with enhanced viral replication and slightly accelerated mortality [41]. These results suggest several mechanisms to explain why glucocorticoid therapy may be of limited benefit in the overall picture of pneumovirus infection. Interestingly, Thomas and colleagues [42] also determined that glucocorticoids had no impact on the virus-induced chemokine response in hRSV infection in human subjects.

35.7.3 Combination Therapy with Ribavirin and Specific Immunomodulatory Agents

Given our earlier observation on the crucial nature of the chemokine, MIP-1α, in promoting granulocyte recruitment in response to virus infection, we considered the possibility that blockade of this chemokine itself, or its signaling via its major receptor, CCR1, might provide appropriate immunomodulatory control in this setting. In a series of studies, we found significant improvements in long-term survival when ribavirin was administered to symptomatic mice in conjunction with anti-MIP-1α antibodies, or with small molecule blockade (met-RANTES) of the MIP-1α receptor, CCR1 [31,32] (Fig. 35.6).

Fig. 35.6 Survival of PVM-infected mice treated with combined antiviral and immunomodulatory therapy. Improved survival resulted from treatment with ribavirin and met-RANTES (* p<0.05) compared individually to the groups treated with Met-RANTES alone, ribavirin alone, or PBS. Further improvement was observed in response to combination of ribavirin with the higher met-RANTES dose, 100 µg/day, over that observed in response to ribavirin-met-RANTES at 10 µg/day (** p<0.05), approaching that observed for CCR1 gene-deleted (CCR1 -/-) mice treated with ribavirin, representing theoretical complete receptor blockade. Reprinted with permission from Bonville, et al. [32]
A similar study documented the effectiveness of ribavirin in conjunction with the cysteinyl-leukotriene inhibitor montelukast [43]. Interestingly, although neither agent was effective at reducing morbidity or mortality as single-agent therapy, together, administered to infected, symptomatic mice, significant improvements in long-term survival were observed (50% vs. 10% for PBS control). Interestingly, montelukast had little impact overall on neutrophil recruitment, suggesting that the presence of neutrophils alone does not indicate inevitable progression to intractable disease.

**35.8 Conclusions**

The PVM model holds great promise for the elucidation of inflammatory mechanisms associated with virus infection and acute inflammatory responses in the lung. Studies carried out to date have provided an explanation for the lack of clinical efficacy of antiviral therapy, and have indicated that chemokine and/or chemokine-receptor blockade in conjunction with appropriate antiviral therapy might be more effective than antiviral therapy alone. Likewise, PVM is an excellent system in which to explore the molecular mechanisms through which natural immunity to pneumovirus infection develops, information which may assist in the development of novel vaccines and other prevention strategies.

**Acknowledgements** Ongoing work in our laboratories is supported by the New York Children’s Miracle Network (to JBD) and NIAID Division of Intramural Research (to HFR).

**References**

1. Stevens W W, Falsey A R, Braciale T J (2008) RSV 2007: recent advances in respiratory syncytial virus research, Viral Immunol 21:133–140
2. Miyairi J & DeVincenzo J P (2008) Human genetic factors and respiratory syncytial virus disease severity., Clin Microbiol Rev 21:686–703
3. Melero J A (2007) Molecular biology of human respiratory syncytial virus. In: Respiratory Syncytial Virus, Perspectives in Medical Virology (Cane, P. A., ed.), vol. 14, Amsterdam, Elsevier Publishers, pp. 1–42
4. Nokes J D & Cane P A (2008) New strategies for control of respiratory syncytial virus infection, Curr Opin Infect Dis 21:639–643
5. Rosenberg H F, Bonville C A, Easton A J et al (2005) The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention. Pharmacol Ther 105:1–6
6. Easton A J, Domachowske J B, Rosenberg H F (2007) Pneumonia virus of mice. In: Respiratory Syncytial Virus, Perspectives in Medical Virology (Cane, P. A., ed.), vol. 14, Amsterdam, Elsevier Press, pp. 299–319
7. Rosenberg H F, Dyer K D, Domachowske J B (2008) Eosinophils and their interactions with respiratory virus pathogens, Immunol Res (in press)
8. Rosenberg H F & Domachowske J B (2008) Immunol Lett 118:6–12
9. Horsfall F L & Hahn R G (1940) A latent virus in normal mice capable of producing pneumonia in its natural host, J Exp Med 71:391–408
10. Compans R W, Harter D H, Choppin P W (1967) Studies on pneumonia virus of mice (PVM) in cell culture. II. Structure and morphogenesis of the virus particle, J Exp Med 126:267–276
11. Horsfall F L & Ginsberg H S (1951) The dependence of the pathological lesion upon the multiplication and extent of pneumonia, J Exp Med 93:139–150
12. Ginsberg H S & Horsfall F L Jr. (1951) Therapy of infection with pneumonia virus of mice (PVM); effect of a polysaccharide on the multiplication cycles of the virus and on the course of the viral pneumonia, J Exp Med 93:161–171
13. Ginsberg H S & Horsfall F L Jr. (1949) Concurrent infection with influenza virus and mumps virus or pneumonia virus of mice as bearing on the inhibition of virus multiplication by bacterial polysaccharides, J Exp Med 89:37–52
14. Collins P L & Crowe J E Jr. (2007) Chapter 46: Respiratory syncytial virus and metapneumovirus. In: Field's Virology (Knipe, D. M., Howley, P. M., eds.), 5th ed., Lippincott, Williams & Wilkins Publishers, Philadelphia, PA
15. Chambers P, Pringle C R, Easton A J (1992) Sequence analysis of the gene encoding the fusion glycoprotein of pneumonia virus of mice suggests possible conserved secondary structure elements in paramyxovirus fusion glycoproteins, J. Gen Virol 73:1717–1724
16. Barr J & Easton A J (1995) Characterisation of the interaction between the nucleoprotein and phosphoprotein of pneumonia virus of mice, Virus Res 39:221–235
17. Easton A J & Chambers P (1997) Nucleotide sequence of the genes encoding the matrix and small hydrophobic proteins of pneumonia virus of mice, Virus Res 48:27–33
18. Ahmadian G, Chambers P, Easton A J (1999) Detection and characterisation of proteins encoded by the second ORF of the M2 gene of pneumoviruses, J Gen Virol 80:2011–2016
19. Anh D B, Faisca P, Desmetech D J (2006) Differential resistance/susceptibility patterns to pneumovirus infection among inbred mouse strains, Am. J. Physiol. Lung Cell Mol Physiol 291: L426–L435
20. Domachowske J B, Bonville C A, Easton A J et al (2002) Differential expression of proinflammatory cytokine genes in vivo in response to pathogenic and nonpathogenic pneumovirus infections, J Infect Dis 186:8–14
21. Ellis J A, Martin B V, Waldner C et al (2007) Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice, Vaccine 25:1085–1089
22. Krempf C D & Collins P L (2004) Reevaluation of the virulence of prototypic strain 15 of pneumonia virus of mice, J Virol 78:13362–13365
23. Torple L C & Easton A J (2005) Genome sequence of the non-pathogenic strain 15 of pneumonia virus of mice and comparison with the genome of the pathogenic strain J3666, J Gen Virol 86:159–169
24. Krempf C D, Lamirande E W, Collins P L (2005) Complete sequence of the RNA genome of pneumonia virus of mice (PVM), Virus Genes 30:237–249
25. Domachowske J B, Bonville C A, Dyer K D et al (2000) Pulmonary eosinophilia and production of MIP-1 alpha are prominent responses to infection with pneumonia virus of mice, Cell Immunol 200: 98–104
26. Domachowske J B, Bonville C A, Gao J L et al (2000) The chemokine macrophage-inflammatory protein-1 alpha and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J Immunol 165:2677–2682
27. Bonville C A, Bennett N J, Koehnlein M et al., (2006) Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bronchiolitis. Virology 349:87–95
28. Welliver T P, Garofalo R P, Hosakote Y et al., (2007) Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses, J Infect Dis 195:1126–1136
29. Easton A J, Domachowske J B, Rosenberg H F (2004) Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev 17: 390–412
30. Cook D N, Beck M A, Coffman T M et al. (1995) Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 269:1583–1585
31. Bonville C A, Easton A J, Rosenberg H F et al. (2003) Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents, J Virol 77:1237–1244
32. Bonville C A, Lau V K, DeLeon J M et al. (2004) Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J Virol 78:7984–7989
33. Bonville C A, Percopo C M, Dyer K D et al. (2009) Inflammatory responses to pneumovirus infection: interferon-gamma is necessary for CCL3-mediated neutrophil recruitment in vivo. BMC Immunol (In preparation)
34. Looney R J, Falsey A R, Walsh E et al. (2002) Effect of aging on cytokine production in response to respiratory syncytial virus infection, J Infect Dis 185:682–685
35. Bonville C A, Percopo C M, Dyer K D et al. (2007) Diminished inflammatory responses to natural pneumovirus infection among older mice. Virology 368:182–190
36. Garvey T L, Dyer K D, Ellis J A et al. (2005) Inflammatory responses to pneumovirus infection in IFNαβR gene-deleted mice, J Immunol 175: 4735–4744
37. Prince G A, Curtis S J, Yim K C et al. (2001) Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine, J Gen Virol 82:2881–2888
38. Percopo C M, Phipps S, Foster P S et al. (2009) Pulmonary eosinophils and their role in immunopathology associated with formalin-fixed pneumovirus vaccination, J Immunol (in review)
39. Ventre K & Randolph A G (2007) Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children, Cochrane Database Syst Rev 1:CD000181
40. Patel H, Platt R, Lozano J M et al. (2004) Glucocorticoids for acute viral bronchiolitis in infants and young children, Cochrane Database Syst Rev 3: CD004878
41. Domachowske J B, Bonville C A, Ali-Ahmad D et al. (2001) Glucocorticoid administration accelerates mortality of pneumovirus-infected mice. J Infect Dis 184:1518–1523
42. Thomas L H, Sharland M, Friedland J S (2002) Steroids fail to down-regulate respiratory syncytial virus-induced IL-8 secretion in infants, Pediatr Res 52:368–372
43. Bonville C A, Rosenberg H F, Domachowske J B (2006) Ribavirin and cysteinyl leukotriene-1 receptor blockade as treatment for severe bronchiolitis, Antiviral Res 69:53–59